Skip to main content
. Author manuscript; available in PMC: 2009 Nov 25.
Published in final edited form as: Vaccine. 2008 Oct 1;26(50):6329–6337. doi: 10.1016/j.vaccine.2008.09.031

Figure 4.

Figure 4

Comparison of humoral immune responses of mice to VSV-ssLcrV1 and VSV-LcrV1 vaccinations. (A) Timeline for dose response vaccination-challenge study. Mice were vaccinated IM with 107, 108 and 109 pfu doses of rVSVs encoding either ssLcrV or LcrV and challenged IN with Y. pestis (CO92 strain). VSV-eGFP1 immunization (107 pfu) was used as control. (B) Anti-LcrV titer profile at 56 and 82 days post immunization, in mice immunized with 107, 108 and 109 pfu doses of either VSV-ssLcrV1 (left panel) or VSV-LcrV1 (right panel). (C) Amount of anti-LcrV specific IgG1 and IgG2a isotypes in VSV-ssLcrV1 (left) of VSV-LcrV1 (right) vaccinated mice in the 109 pfu dose group. Serum antibodies that bound LcrV were quantitated using secondary IgG1- and IgG2-specific antibodies. Concentrations of mouse IgG1 or IgG2a were then calculated from standard curves run in parallel using a range of concentrations of purified mouse IgG1 or IgG2a.